Biocartis, Invetech Ink Deal Covering Biomarker Analysis Platform | GenomeWeb

NEW YORK (GenomeWeb News) – Invetech will support the development and manufacture of Biocartis' multiplex platform for biomarker analysis under an agreement announced today.

Invetech will support the development of Biocartis' Evaluation instrument for analyzing protein and nucleic acid-based biomarkers to support clinical research and pharmaceutical applications, the partners said. Evaluation "provides an integrated reaction and detection environment," while enabling the simultaneous investigation of multiple analytes per sample, the companies added.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

Widespread genome sequencing might not be justified just yet, USA Today reports.